韩国举行咨询会议，以促进人工智能（AI）在药物开发中的使用

据Yonhap新闻社报道，该会议将来自经济和财政部以及其他相关政府机构的官员与包括Daewoong Pharmaceutical在内的领先的制药公司一起。

South Korea is aiming to become a global leader in artificial intelligence (AI) technology, with a focus on promoting the use of AI in drug development, in response to the intensifying global competition in the bio-health sector, the Ministry of Economy and Finance said on Thursday.

经济和金融部周四表示，韩国的目标是成为人工智能（AI）技术的全球领导者，重点是促进AI在药物开发中的使用，以应对生物健康部门的全球竞争。

The ministry held a consultative meeting with private sector stakeholders to discuss ways to foster an environment where AI can be effectively utilized in drug development, Yonhap news agency reported.

据Yonhap News Agency报道，该部与私营部门利益相关者举行了一次咨询会议，讨论了可以有效利用AI的环境的方法。

Officials from the ministry and other relevant government agencies attended the meeting, along with executives from major pharmaceutical companies, including Daewoong Pharmaceutical.

该部和其他相关政府机构的官员以及包括Daewoong Pharmaceutical在内的主要制药公司的高管参加了会议。

The meeting served as a platform to listen to the challenges faced by the pharmaceutical industry and to explore directions for public-private cooperation in promoting AI-based drug development and effective data usage, the Ministry said.

该部称，这次会议是聆听制药行业面临的挑战，并探讨公私合作方面促进基于AI的药物开发和有效数据使用方面的挑战。

The global AI biotechnology market is expected to grow over 19 per cent annually, reaching $7.75 billion by 2029, while South Korea currently ranks third in the world in the number of AI bio-related patent applications.

预计全球AI生物技术市场每年增长超过19％，到2029年将达到77.5亿美元，而韩国目前在与AI Bio相关的专利申请的数量中排名全球第三。

"AI is rapidly permeating the entire biotechnology industry," the finance ministry said. "It is emerging as a core technology across areas, such as new drug development, protein structure prediction and design, and gene therapy."

财政部说：“ AI正在迅速渗透到整个生物技术行业。” “它正在成为跨领域的核心技术，例如新药开发，蛋白质结构预测和设计以及基因治疗。”

The ministry stressed that countries are now in fierce competition to preemptively secure AI capabilities and apply them effectively in the bio-health field.

该部强调，各国现在处于激烈的竞争中，以先发制人的AI能力并有效地应用于生物健康领域。

In particular, AI-powered drug development is revolutionizing the traditional pharmaceutical research and development process, the ministry said.

该部说，特别是AI驱动的药物开发正在彻底改变传统的制药研究和开发过程。

Meanwhile, South Korea plans to pour 60 billion won (about $40.4 million) by 2028 to expand infrastructure for the development of materials and components technologies crucial for advanced industries, such as AI, the Ministry of Trade, Industry, and Energy said on Thursday.

同时，韩国计划在2028年之前倒600亿韩元（约40040万美元），以扩大基础设施，以开发对AI，贸易，工业部和能源部等高级行业至关重要的材料和组件技术。

The investment will be used to build research facilities and equipment for the development and testing of technologies related to materials and components essential for AI, advanced bio, and other future industries, the ministry said.

该部表示，这项投资将用于建造研究设施和设备，以开发和测试与AI，Advanced Bio和其他未来行业所必需的材料和组件相关的技术。

In particular, the government will support the construction of infrastructure for the development of core materials for next-generation AI chips, messenger RNA-based drugs, and others, the ministry said.

该部表示，政府将支持基础设施的建设，以开发下一代AI芯片，基于Messenger RNA的药物等核心材料。